

# Pharmacy BULLETIN BOARD

Hospital Issue ■ Monday November 3, 2014

 For Hemorrhoid Treatment Options, Think About **Odan Labs** And Its Great  
ANORECTAL THERAPY PRODUCTS

**Anodan-HC® OINTMENT & SUPPOSITORIES**

Same active ingredients as ANUSOL-HC

**(Hydrocortisone Acetate • Zinc Sulfate Monohydrate)**

Oint: 15 and 30 g DIN 02128446 / Supp: 12 and 24 DIN 02236399

**Proctodan-HC® OINTMENT & SUPPOSITORIES**

Same active ingredients as ANUGESIC-HC

**(Pramoxine HCl • Hydrocortisone Acetate • Zinc Sulfate)**

Oint: 15 and 30 g DIN 02247322 / Supp: 12 DIN 02247882

**Proctol® OINTMENT & SUPPOSITORIES**

Same active ingredients as PROCTOSEDYL

**(Hydrocortisone • Framycetin Sulfate • Cinchocaine HCl • Esculin)**

Oint: 15 and 30 g DIN 02234466 / Supp: 12 and 24 DIN 02240851

Covered by most private insurance plans and provincial formularies

 To order, please contact your wholesaler or reach Odan directly by phone at  
1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com).

**Now Listed on the Ontario Formulary**
**Taro-Testosterone**

Testosterone Undecanoate Capsules 40 mg

- Bioequivalent and Interchangeable with Andriol®<sup>1</sup>
- High Quality, Lower Price Alternative
- Androgen; testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone<sup>2</sup>

DIN: 02421186

Size	UPC	Wholesaler		
		Mckesson	K&F	McMahon
60	063691075252	071138	149748	10074980
120	063691073333	071136	149837	10075001

 For more information, or to place an order for Taro-Diclofenac topical solution 1.5%, please contact your Taro Representative, your wholesaler, our Customer Service department at 1-800-268-1975 or visit our Website at [www.taro.ca](http://www.taro.ca).

<sup>1</sup>Data on file, Taro Pharmaceuticals Inc.

<sup>2</sup>Taro-Diclofenac Product Monograph.

<sup>3</sup>Pennsaid is a registered trademark of Nuvo Research Inc.

TARO is a registered trademark of Taro Pharmaceuticals Inc.


**Now Listed as Interchangeable on the Ontario Formulary (OFI)**
**P<sup>r</sup>Taro-Diclofenac**

Diclofenac Sodium Topical Solution 1.5%

- Bioequivalent and interchangeable with Pennsaid®<sup>1</sup>
- High Quality, Lower Price Alternative
- Topical Anti-inflammatory; Analgesic<sup>2</sup>
- New Convenient 150 mL Size

Topical Solution 1.5%

DIN: 02420988

Size	UPC	Wholesaler			
		McKesson	K&F	Procurity	McMahon
2 x 60 mL	063691073517	060770	147411	256323	10071421
150 mL	063691073548	060771	147409	256480	10071400

 For more information, or to place an order for Taro-Diclofenac topical solution 1.5%, please contact your Taro Representative, your wholesaler, our Customer Service department at 1-800-268-1975 or visit our Website at [www.taro.ca](http://www.taro.ca).

<sup>1</sup>Data on file, Taro Pharmaceuticals Inc.

<sup>2</sup>Taro-Diclofenac Product Monograph.

<sup>3</sup>Pennsaid is a registered trademark of Nuvo Research Inc.

TARO is a registered trademark of Taro Pharmaceuticals Inc.

**FROM THE NEWSWIRE**

**OTTAWA:** Health Canada has released the October 2014 issue of the Canadian Adverse Reaction Newsletter (CARN). This issue includes an article on diabetes drugs known as incretin-based therapies and a possible association with pancreatic cancer. It also includes an article on the potential risk of liver injury associated with a steroid drug called methylprednisolone when it is injected intravenously (into a vein).

**OTTAWA:** Canadians should be careful to put the latest health care spending figures for Canada into proper perspective. The federally-funded Canadian Institute for Health Information (CIHI) reported on Oct. 30 that growth in health spending is at a 17-year low.

**DORVAL, QC:** Canadians living with psoriasis deserve so much more. Novartis has launched the international Skin Impressions campaign which aims to break down barriers that prevent people with severe skin diseases from living their lives to the fullest. Novartis Pharmaceuticals Canada Inc. wants to raise awareness that psoriasis is so much more than a skin disease and has severe impact on quality of life.